ALMOTRIPTAN MALATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ALMOTRIPTAN MALATE (ALMOTRIPTAN MALATE).
Selective serotonin 5-HT1B/1D receptor agonist; cranial vasoconstriction and inhibition of trigeminal nerve transmission.
| Metabolism | Metabolized by CYP3A4 and MAO-A; almotriptan is not significantly metabolized via MAO. |
| Excretion | Approximately 70% renal excretion (40% unchanged, 30% as metabolites), 30% fecal/biliary elimination. |
| Half-life | Terminal elimination half-life: 3-4 hours. In patients with hepatic impairment, half-life may be prolonged (up to 6-7 hours), necessitating dose adjustment. |
| Protein binding | Approximately 20%, primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 180-200 L (approx. 2.6-2.9 L/kg). Indicates extensive extravascular distribution, correlating with tissue binding and CNS penetration. |
| Bioavailability | Oral: approximately 70% due to moderate first-pass metabolism; unaffected by food. |
| Onset of Action | Oral: 30-60 minutes; headache relief typically begins within 1-2 hours. |
| Duration of Action | 4-6 hours; clinical efficacy may last up to 24 hours with sustained headache relief in some patients. |
12.5 mg orally at onset of migraine; may repeat after 2 hours if headache recurs. Maximum 25 mg/day.
| Dosage form | TABLET |
| Renal impairment | CrCl 10-39 mL/min: maximum dose 12.5 mg per 24-hour period. CrCl <10 mL/min: contraindicated. |
| Liver impairment | Child-Pugh class A or B: maximum dose 12.5 mg per 24-hour period. Child-Pugh class C: contraindicated. |
| Pediatric use | Adolescents ≥12 years: 6.25 mg or 12.5 mg orally at onset; may repeat after 2 hours. Maximum 25 mg/day. Children <12 years: safety and efficacy not established. |
| Geriatric use | Use caution due to increased risk of cardiovascular and hepatic impairment; consider lower starting dose of 6.25 mg. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ALMOTRIPTAN MALATE (ALMOTRIPTAN MALATE).
| Breastfeeding | Almotriptan is excreted into human breast milk. The relative infant dose (RID) is approximately 1.5% of the maternal weight-adjusted dose; milk-to-plasma ratio (M/P) is 2.7 (for the parent drug) but the active metabolite accounts for additional exposure. Caution is advised; consider delaying breastfeeding for 12 hours after dosing, or avoid use in nursing mothers if alternative agents are available. |
| Teratogenic Risk | Pregnancy Category C. No adequate well-controlled studies in pregnant women. In animal studies, almotriptan produced embryolethality and fetal malformations (including cleft palate and ventricular septal defect) at doses producing maternal toxicity. Use only if potential benefit justifies potential risk to fetus. First trimester: limited data, cannot exclude risk. Second and third trimesters: unknown risk; avoid prolonged use due to potential for uterine hypertonus or decreased placental perfusion. |
■ FDA Black Box Warning
No FDA boxed warning.
| Serious Effects |
["History of ischemic heart disease","Coronary artery vasospasm (including Prinzmetal's variant)","Cerebrovascular syndromes (e.g., stroke, TIA)","Peripheral vascular disease","Uncontrolled hypertension","Hemiplegic or basilar migraine","Concomitant use with ergotamine derivatives","Severe hepatic impairment","Hypersensitivity to almotriptan"]
| Precautions | ["Serotonin syndrome (especially with SSRIs/SNRIs)","Cardiac ischemia and/or infarction","Cerebral hemorrhage","Coronary artery vasospasm","Increased blood pressure","Medication overuse headache"] |
| Food/Dietary | No significant food interactions reported. Grapefruit juice is not known to interact. Almotriptan can be taken with or without food. |
Loading safety data…
| Fetal Monitoring | No specific fetal monitoring recommended. Maternal monitoring: blood pressure and heart rate during intravenous administration; observe for signs of serotonin syndrome if used with other serotonergic drugs. In third trimester, consider fetal heart rate monitoring if used for prolonged periods due to potential uteroplacental vasoconstriction. |
| Fertility Effects | In animal studies, no adverse effects on fertility were observed at oral doses up to 200 mg/kg/day (approximately 100 times the human daily dose of 12.5 mg based on body surface area). No human data on fertility effects. Theoretical risk of impaired fertility due to vascular constriction or hormonal effects is not substantiated. |
| Clinical Pearls | Almotriptan is a 5-HT1B/1D receptor agonist used for acute migraine treatment. Onset of action is within 30-60 minutes. Bioavailability is about 70%, higher than other triptans. It is partially metabolized by MAO-A, so avoid MAOIs. No dosage adjustment needed for mild to moderate hepatic impairment. Contraindicated in patients with history of ischemic heart disease, cerebrovascular disease, or uncontrolled hypertension. Maximum dose is 25 mg per day. |
| Patient Advice | Take one tablet as soon as migraine symptoms appear. Do not exceed 25 mg in 24 hours. · Do not take within 24 hours of other triptans or ergotamine-containing medications. · Inform your doctor if you have risk factors for coronary artery disease, such as high blood pressure, high cholesterol, smoking, obesity, diabetes, or family history of heart disease. · Seek emergency medical attention if you experience chest pain, shortness of breath, or irregular heartbeat after taking this medication. · Avoid driving or operating machinery until you know how almotriptan affects you, as it may cause dizziness or drowsiness. · Store at room temperature away from moisture and heat. |